【摘要】 目的评价头孢吡肟(马斯平)与舒巴坦/头孢哌酮(舒普深)治疗儿童呼吸系统中重度细菌性感染的疗效及安全性。方法采用随机、双盲、对照的临床病例研究方法,100例住院中重度细菌性肺炎儿童随机分成2组,一组(A组)应用马斯平,按每次50mg/kg·b.w.,疗程5~10d;另一组(B组)用舒普深,按每日50~100mg/kg·b.w.,2组均每日2次给药静脉滴注,疗程5~10d,观察两组药物的疗效及不良反应发生率。疗效判断标准如下,痊愈:临床症状与体征完全消失;显效:临床症状与体征明显好转或大部分消失;无效:临床症状与体征无缓解甚至加重;复发:临床症状与体征缓解后再次加重。结果马斯平组痊愈44例、显效5例、无效1例、复发0例,总有效率为98%,50例中均未出现不良反应;舒普深组痊愈40例、显效6例、无效4例、复发0例,总有效率为92%,50例中有1例出现皮疹,第2天消失,未停药。两组疗效比较,χ2=2.43,P>0.05,差异无显著性意义。结论马斯平治疗儿童呼吸系统中重度细菌性感染的疗效显著,安全性好;舒普深治疗儿童呼吸系统中重度细菌性感染的疗效显著,安全性好;马斯平与舒普深具有同等的疗效和安全性。更多还原

【Abstract】 Objectives To evaluate the therapeutic effects and safety of cefepime (Maxipime) and sulbactam/cefoperazone (sulperazone) on moderate and severe respiratory infection in children. Methods Totally 100 children hospitalized for pneumonia were randomized equally into 2 groups, namely group A with maxipime treatment at the dose of 50 mg/kg given intravenously twice daily, and group B with sulperazone treatment at 50-100 mg/kg given intravenously twice a day. The therapeutic effects and safety of both medications were observed. Results In maxipime group, 44 of the 50 cases were cured with complete elimination of the symptoms and signs, and obvious therapeutic effect was achieved in 5 cases with significant improvement or resolution of the majority of symptoms and signs. One case failed to respond favorably to the treatment, with the overall efficacy rate of 98% without incidence of adverse effects. In sulperazone group, 40 of the 50 cases were cured, 6 showed significant improvement, and 4 failed to respond to the treatment, with the rate of 92%. One patient complained of rashes during sulperazone treatment, which disappeared the next day without sulperazone withdrawal. Significant difference was not noted between the groups (χ2=2.43, P>0.05). Conclusions Both maxipime and sulperazon are effective and safe for application in children with moderate and severe respiratory infections.更多还原